Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck
Sponsor: National Cancer Institute (NCI)
A PHASE2 clinical study on Lip and Oral Cavity Squamous Cell Carcinoma and Oral Cavity Verrucous Carcinoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 11 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Feb 2021 — Dec 2022 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Unknown Status PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .